The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1144
November 25, 2002
View Complete Issue         Table of Contents 2019 
Hemolysis From Ceftriaxone
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Hemolysis From Ceftriaxone
November 25, 2002 (Issue: 1144)
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Hemolysis From Ceftriaxone
Article code: 1144b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.